Jochen Klueppel

Managing Director, Venture Capital, Technology Investor, Innovation Scout

πŸ“ Stuttgart Region, GermanyπŸ”„ Updated July 2026πŸ’Ό 8 investmentsπŸ“… 24 years investingπŸ—“ Last invested Jan 2016
VC🌍 Germany
8
Total investments
1
Early stage
1
Mid stage
0
Late stage
24y
Years active

Portfolio

2 investments Β· sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
2004
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Twitter: https://twitter.com/immatics Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
Past Investor
2002
Quantenna (Nasdaq:QTNA) is the global leader and innovator of high performance Wi-Fi solutions. Founded in 2006, Quantenna has demonstrated its leadership in Wi-Fi technologies with many industry firsts into the market. Quantenna continues to innovate with the mission to perfect Wi-Fi by establishing benchmarks for speed, range, efficiency and reliability. Quantenna takes a multidimensional approach, from silicon, system to software, to assess Wi-Fi networks and provides total solutions for service providers worldwide.
Experience Β· 9 entries
All (9)
Investments (8)
2016
SMACC GmbH, Merolt, Lingoda, Hoomn, YEAY
Investor
Jan 2016
2014
Reelio, Ayoxxa, Tiny Inspector, GYANT, Zageno, Carma
Investor
2014
2007
moviepilot GmbH
Investor and Fan
2007
2004
Investor
2004
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Twitter: https://twitter.com/immatics Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
2002
Partner
Feb 2002
Based in Stuttgart, Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, we predominantly work with our own capital that we invest as entrepreneurs. This results in the following advantages and benefits for our portfolio companies: - independence - understanding for the situation and matter at hand - fast and pragmatic decision making Grazia contributions range from a few hundred thousand to several million Euros per investment. Grazia focuses on Europe and in particular, Germany. Grazia co-invests in selected situations in the USA. Having invested through two severe financial market crises, Grazia has proven that we weather stormy times. At the end of the day, fairness, empathy and passion are the essential values that shape our decisions, actions and our lives.
Show all 9 entries ↓
Investment activity
2002–2016 Β· 8 investments
2002420041200712014120161
Recent (last 2 years)Earlier